Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

Alkermes plc (Nasdaq: ALKS) is all set to release its fourth quarter and year-end 2025 financial results on Wednesday, Feb. 25, 2026. The company will be hosting a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on the same day to discuss the results and provide an update on the company.

With a strong track record of delivering innovative treatments for serious and chronic diseases, Alkermes has become a leading pharmaceutical company in the industry. The company’s commitment to developing transformative therapies for patients has earned it a strong reputation among investors and the medical community alike.

The upcoming conference call and webcast presentation will provide an opportunity for investors, analysts, and the general public to gain insights into Alkermes’ financial performance and future plans. The call will feature top management executives who will discuss the company’s financial results for the fourth quarter and year-end 2025, as well as provide an outlook for the year ahead.

In addition to discussing financial results, management will also provide an update on the company’s pipeline and ongoing research and development projects. This will give stakeholders a chance to learn about Alkermes’ progress in developing new treatments and expanding its product portfolio.

The webcast player and accompanying presentation materials will be available on Alkermes’ website, providing easy access to those who are unable to attend the conference call in person. The webcast will also be archived on the website for future reference.

Alkermes has been consistently delivering strong financial results, and the fourth quarter and year-end 2025 results are expected to be no different. The company has a diverse portfolio of products that cater to a wide range of diseases and disorders, providing a steady source of revenue.

Moreover, Alkermes has a strong pipeline of potential treatments, with several products in different stages of clinical trials. These promising candidates have the potential to address unmet medical needs and bring significant value to the company and its shareholders.

The conference call and webcast presentation will also include discussions on financial expectations for 2026. This will give investors and stakeholders a glimpse into the company’s future plans and strategies, allowing them to make well-informed decisions.

With its strong financial performance and promising pipeline, Alkermes is well-positioned for growth and success in the years to come. The company’s dedication to improving the lives of patients and creating value for shareholders has made it a top choice among investors.

So mark your calendars for Wednesday, Feb. 25, 2026, at 8:00 a.m. ET (1:00 p.m. GMT) and join Alkermes for its conference call and webcast presentation. Don’t miss this opportunity to learn more about the company’s progress and future plans. We look forward to sharing our exciting updates with you.